An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures
Phase of Trial: Phase IV
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Retigabine (Primary) ; Antiepileptic drugs
- Indications Partial epilepsies
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 28 Aug 2017 Status changed from recruiting to discontinued.
- 28 Sep 2016 Planned End Date changed from 1 Feb 2019 to 1 Nov 2025.
- 28 Sep 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Nov 2025.